Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes.

Next Previous
Trial Profile

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUMINOUS
  • Sponsors Novartis; Novartis Ophthalmics; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Aug 2022 Results assessing the mean change in visual acuity, treatment exposure over year 1 and 5-year safety in treatment-naive central retinal vein occlusion patients, published in the Eye.
    • 20 May 2016 Status changed from recruiting to completed.
    • 03 Mar 2016 Planned number of patients changed from 26146 to 30000 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top